Skip to main content
Terug
Watch Compare

NEPHROS INC

Datakwaliteit: 100%
NEPH
NASDAQ Manufacturing Measuring & Analyzing Instruments
€ 2,87
▼ € 0,10 (-3,21%)
Marktkapitalisatie: 31,51 M
Prijs
€ 2,96
Marktkapitalisatie
31,51 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 15,92% annually over 5 years — strong growth
Earnings grew 1513,51% over the past year
ROE of 12,18% — decent returns on equity
Generating 1,59 M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 16,75%
Cash machine — converts 133,17% of earnings into free cash flow

Groei

Revenue Growth (5Y)
15,92%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)32,67%
Earnings (1Y)1513,51%
FCF Growth (3Y)45,41%

Kwaliteit

Return on Equity
12,18%
Boven sectorgemiddelde (-54,01%)
ROIC10,68%
Net Margin6,35%
Op. Margin6,10%

Veiligheid

Debt / Equity
N/A
Current Ratio4,34
Interest Coverage1146,00

Waardering

PE (TTM|NTM|2027)
26,39 | 22,77 | 22,77
Boven sectorgemiddelde (-1,49)
P/B Ratio3,15
EV/EBITDA20,48
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E 26,4 -1,5
P/B 3,2 1,6
ROE % 12,2 -54,0
Net Margin % 6,4 -41,5
Rev Growth 5Y % 15,9 1,8
D/E — 0,3

Koersdoel Analisten

2 analisten
Strong Buy
Huidig
€ 2,87
+144.3%
Koersdoel
€ 7,00
€ 6,00
€ 7,00
€ 8,00
Vooruitzicht
Forward K/W 22,77
Forward WPA € 0,13
WPA Groei (sch.) +116,7%
Omzet Sch. 22,86 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,13
€ 0,13 – € 0,13
 22,86 M 1
FY2026 € 0,06
€ 0,06 – € 0,06
 20,47 M 2

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 € 0,01 € 0,01 0,0%
Q32025 -€ 0,02 € 0,03 +250,0%
Q22025 -€ 0,03 € 0,02 +180,0%
Q12025 -€ 0,01 € 0,05 +1100,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 32,67% Revenue Growth (3Y) 14,88%
Earnings Growth (1Y) 1513,51% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 15,92% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 18,79 M Net Income (TTM) 1,19 M
ROE 12,18% ROA 9,37%
Gross Margin 61,87% Operating Margin 6,10%
Net Margin 6,35% Free Cash Flow (TTM) 1,59 M
ROIC 10,68% FCF Growth (3Y) 45,41%
Safety
Debt / Equity N/A Current Ratio 4,34
Interest Coverage 1146,00 Asset Turnover 1,47
Working Capital 8,24 M Tangible Book Value 8,92 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 26,39 Forward P/E 22,77
P/B Ratio 3,15 P/S Ratio 1,68
PEG Ratio N/A Forward PEG 0,20
EV/EBITDA 20,48 Fwd EV/EBITDA N/A
Forward P/S 1,38 Fwd Earnings Yield 4,39%
FCF Yield 5,05%
Market Cap 31,51 M Enterprise Value 26,34 M
Per Share
EPS (Diluted TTM) 0,11 Revenue / Share 1,77
FCF / Share 0,15 OCF / Share 0,15
EPS CAGR (1Y) 1000,00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,29% FCF Conversion 133,17%
SBC-Adj. FCF 1,31 M Growth Momentum 16,75

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 18,79 M 14,16 M 14,24 M 9,98 M 10,40 M
Net Income 1,19 M 74.000,0 -1,58 M -7,11 M -3,87 M
EPS (Diluted) 0,11 0,01 -0,15 — —
Gross Profit 11,63 M 8,72 M 8,41 M 4,73 M 5,74 M
Operating Income 1,15 M 6.000,0 -1,59 M -4,34 M -4,34 M
EBITDA — — — — —
R&D Expenses 1,34 M 906.000,0 873.000,0 1,26 M 2,17 M
SG&A Expenses 9,00 M 7,68 M 8,91 M 7,59 M 7,71 M
D&A 140.000,0 135.000,0 214.000,0 218.000,0 202.000,0
Interest Expense 1.000,0 1.000,0 2.000,0 20.000,0 41.000,0
Income Tax 12.000,0 15.000,0 0,0 0,0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 13,64 M 11,21 M 11,86 M 11,00 M 17,65 M
Total Liabilities 3,44 M 2,63 M 3,50 M 2,12 M 2,90 M
Shareholders' Equity 10,20 M 8,59 M 8,36 M 5,59 M 11,70 M
Total Debt — — — 71.000,0 343.000,0
Cash & Equivalents 5,40 M 3,76 M 4,31 M 3,63 M 6,97 M
Current Assets 11,22 M 8,30 M 8,41 M 8,26 M 13,63 M
Current Liabilities 2,77 M 1,56 M 2,11 M 1,41 M 2,39 M